These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 6844370)

  • 21. Vascular symptoms in patients with primary Raynaud's phenomenon are not exacerbated by propranolol or labetalol.
    Steiner JA; Cooper R; Gear JS; Ledingham JG
    Br J Clin Pharmacol; 1979 Apr; 7(4):401-3. PubMed ID: 375960
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of lisinopril or lisinopril/hydrochlorothiazide compared with adjusting of previous medication and intensifying non-pharmacological treatment in patients with mild to moderate hypertension.
    Keinänen-Kiukaanniemi S; Rasmusen M; Pekkarinen T; Pitkäjärvi T; Romo M; Takala J
    Arzneimittelforschung; 1997 Feb; 47(2):144-50. PubMed ID: 9079233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does labetalol predispose to pulmonary edema in severe pregnancy-induced hypertensive disease?
    Gilson GJ; Kramer RL; Barada C; Izquierdo LA; Curet LB
    J Matern Fetal Med; 1998; 7(3):142-7. PubMed ID: 9642612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Labetalol for hypertension.
    Drug Ther Bull; 1978 Nov; 16(23):89-90. PubMed ID: 699758
    [No Abstract]   [Full Text] [Related]  

  • 25. Labetalol ('trandate') in hypertension: a multicentre study in general practice.
    Gomez G; Phillips LA
    Curr Med Res Opin; 1980; 6(10):677-84. PubMed ID: 7428406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of labetalol, hydrallazine, and propranolol in the therapy of moderate hypertension.
    West MJ; Wing LM; Mulligan J; Walkley J; Grygiel JJ; Graham JR; Chalmers JP
    Med J Aust; 1980 Mar; 1(5):224-5. PubMed ID: 6990215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
    Levine B
    Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of long-term high-dose labetalol on blood pressure in patients with severe hypertension resistant to previous therapy.
    Kristensen BO; la Cour Petersen E
    Postgrad Med J; 1980; 56 Suppl 2():57-9. PubMed ID: 7433344
    [No Abstract]   [Full Text] [Related]  

  • 29. A comparison of scalp tingling, thirst and polyuria in patients on labetalol and metoprolol.
    Coulter DM
    N Z Med J; 1979 Nov; 90(647):397. PubMed ID: 293566
    [No Abstract]   [Full Text] [Related]  

  • 30. [Clinical trial of labetalol (Tranedate) in general practice].
    Mathisen R; Sveen K
    Tidsskr Nor Laegeforen; 1983 Feb; 103(5):541-3. PubMed ID: 6223408
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparative study of oxdralazine and dihydralazine in essential hypertension.
    Salvadeo A; Villa G; Segagni S; Piazza W; Criscuolo D
    Int J Clin Pharmacol Ther Toxicol; 1981 Aug; 19(8):372-6. PubMed ID: 7030978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A dose-ranging study of labetalol in moderate to moderately severe hypertension.
    Darmansjah I; Setiawati A; Prabowo P; Sukandar E; Parsoedi I; Ardaya ; Bahry B; Jusman J; Anggraeni E
    Int J Clin Pharmacol Ther; 1995 Apr; 33(4):226-31. PubMed ID: 7620693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Labetalol. Current research and therapeutic status.
    Wallin JD; O'Neill WM
    Arch Intern Med; 1983 Mar; 143(3):485-90. PubMed ID: 6338850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous labetalol in severe hypertension. Effects on blood pressure, plasma renin activity and catecholamines.
    Lechi A; Picotti GB; Covi G; Pomari S; Pedrolli E; Cesura AM; Danti G; Mattioli M
    Arzneimittelforschung; 1981; 31(3):524-6. PubMed ID: 7013770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Usefulness of combined captopril-labetalol treatment in resistant hypertension (author's transl)].
    El Matri A; Larabi MS; Kheder A; Belkahia C; Kechrid C; Ben Maiz H; Ben Ayed H
    Nouv Presse Med; 1982 May; 11(21):1611-3. PubMed ID: 7048251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Beta blockers and disturbances of the microcirculation (author's transl)].
    Cloarec M; Graisely B; Dumas R; Chermet J; Gilbert JC; Debray J
    J Mal Vasc; 1980; 5(2):123-4. PubMed ID: 6109751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical, ergometric and polygraphic evaluation of the effects of metoprolol and labetalol administration in essential arterial hypertension. Comparative study].
    Schirripa V; Attisano N; Sarica G; Grenci G; Martelli G
    Minerva Med; 1982 Apr; 73(14):845-9. PubMed ID: 7070696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Labetalol in inadequately controlled hypertensive patients. A twice-daily oral regimen.
    Douglas-Jones AP
    Practitioner; 1980 Aug; 224(1346):841-4. PubMed ID: 7433403
    [No Abstract]   [Full Text] [Related]  

  • 40. Minoxidil and labetalol: very effective antihypertensive combination.
    Whiting G; Craswell P; Boyle P; Bett N
    Med J Aust; 1980 Mar; 1(5):225-6. PubMed ID: 7374568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.